EPRX Stock Overview
A clinical stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Eupraxia Pharmaceuticals Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$2.65 |
| 52 Week High | CA$5.58 |
| 52 Week Low | CA$2.39 |
| Beta | 1.23 |
| 11 Month Change | 8.16% |
| 3 Month Change | 5.37% |
| 1 Year Change | -49.04% |
| 33 Year Change | 22.44% |
| 5 Year Change | n/a |
| Change since IPO | -4.98% |
Recent News & Updates
Recent updates
Shareholder Returns
| EPRX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0.8% | -0.5% | 0.3% |
| 1Y | -49.0% | 18.0% | 32.4% |
Return vs Industry: EPRX underperformed the US Biotechs industry which returned 17.6% over the past year.
Return vs Market: EPRX underperformed the US Market which returned 32.5% over the past year.
Price Volatility
| EPRX volatility | |
|---|---|
| EPRX Average Weekly Movement | 10.2% |
| Biotechs Industry Average Movement | 10.0% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 15.0% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: EPRX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: EPRX's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 29 | James Helliwell | www.eupraxiapharma.com |
Eupraxia Pharmaceuticals Inc., a clinical stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector. The company’s lead product candidates are EP-104IAR, which is in a Phase III clinical trial for the treatment of unmet medical needs and for pain relief for knee osteoarthritis; EP-104GI, which is in a Phase II clinical trial for the treatment of eosinophilic esophagitis; and EP-104, under preclinical studies for the treatment of other inflammatory joint conditions, benign structures of the esophagus, and epidural delivery. It also is involved in the development of product candidates for oncology.
Eupraxia Pharmaceuticals Inc. Fundamentals Summary
| EPRX fundamental statistics | |
|---|---|
| Market cap | US$92.65m |
| Earnings (TTM) | -US$27.00m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-3.5x
P/E RatioIs EPRX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EPRX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$27.00m |
| Earnings | -US$27.00m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.76 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 34.1% |
How did EPRX perform over the long term?
See historical performance and comparison